Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Buy
72
FFTY Quote, Financials, Valuation and Earnings
Last price:
$33.44
Seasonality move
:
-0.78%
Day range:
$32.95 - $33.50
52-week range:
$22.91 - $34.26
Dividend yield:
0.78%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
79.8K
Avg. volume:
64.9K
1-year change:
20.78%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
FFTY
Innovator IBD 50 ETF
|
-- | -- | -- | -- | -- |
|
FPX
First Trust US Equity Opportunities ETF
|
-- | -- | -- | -- | -- |
|
IPO
Renaissance IPO ETF
|
-- | -- | -- | -- | -- |
|
MDYG
SPDR S&P 400 Mid Cap Growth ETF
|
-- | -- | -- | -- | -- |
|
ONEO
SPDR Russell 1000 Momentum Focus ETF
|
-- | -- | -- | -- | -- |
|
TPLE
Timothy Plan US Large/Mid Core Enhanced ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
FFTY
Innovator IBD 50 ETF
|
$33.36 | -- | -- | -- | $0.26 | 0.78% | -- |
|
FPX
First Trust US Equity Opportunities ETF
|
$147.74 | -- | -- | -- | $0.09 | 0.14% | -- |
|
IPO
Renaissance IPO ETF
|
$44.90 | -- | -- | -- | $0.05 | 0.38% | -- |
|
MDYG
SPDR S&P 400 Mid Cap Growth ETF
|
$88.65 | -- | -- | -- | $0.19 | 0.84% | -- |
|
ONEO
SPDR Russell 1000 Momentum Focus ETF
|
$124.70 | -- | -- | -- | $0.42 | 1.35% | -- |
|
TPLE
Timothy Plan US Large/Mid Core Enhanced ETF
|
$27.04 | -- | -- | -- | $0.02 | 0.94% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
FFTY
Innovator IBD 50 ETF
|
-- | 1.890 | -- | -- |
|
FPX
First Trust US Equity Opportunities ETF
|
-- | 1.987 | -- | -- |
|
IPO
Renaissance IPO ETF
|
-- | 1.526 | -- | -- |
|
MDYG
SPDR S&P 400 Mid Cap Growth ETF
|
-- | 1.276 | -- | -- |
|
ONEO
SPDR Russell 1000 Momentum Focus ETF
|
-- | 1.073 | -- | -- |
|
TPLE
Timothy Plan US Large/Mid Core Enhanced ETF
|
-- | 0.969 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
FFTY
Innovator IBD 50 ETF
|
-- | -- | -- | -- | -- | -- |
|
FPX
First Trust US Equity Opportunities ETF
|
-- | -- | -- | -- | -- | -- |
|
IPO
Renaissance IPO ETF
|
-- | -- | -- | -- | -- | -- |
|
MDYG
SPDR S&P 400 Mid Cap Growth ETF
|
-- | -- | -- | -- | -- | -- |
|
ONEO
SPDR Russell 1000 Momentum Focus ETF
|
-- | -- | -- | -- | -- | -- |
|
TPLE
Timothy Plan US Large/Mid Core Enhanced ETF
|
-- | -- | -- | -- | -- | -- |
Innovator IBD 50 ETF vs. Competitors
-
Which has Higher Returns FFTY or FPX?
First Trust US Equity Opportunities ETF has a net margin of -- compared to Innovator IBD 50 ETF's net margin of --. Innovator IBD 50 ETF's return on equity of -- beat First Trust US Equity Opportunities ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital FFTYInnovator IBD 50 ETF-- -- -- FPXFirst Trust US Equity Opportunities ETF-- -- -- -
What do Analysts Say About FFTY or FPX?
Innovator IBD 50 ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust US Equity Opportunities ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Innovator IBD 50 ETF has higher upside potential than First Trust US Equity Opportunities ETF, analysts believe Innovator IBD 50 ETF is more attractive than First Trust US Equity Opportunities ETF.
Company Buy Ratings Hold Ratings Sell Ratings FFTYInnovator IBD 50 ETF0 0 0 FPXFirst Trust US Equity Opportunities ETF0 0 0 -
Is FFTY or FPX More Risky?
Innovator IBD 50 ETF has a beta of 1.319, which suggesting that the stock is 31.878% more volatile than S&P 500. In comparison First Trust US Equity Opportunities ETF has a beta of 1.230, suggesting its more volatile than the S&P 500 by 23.041%.
-
Which is a Better Dividend Stock FFTY or FPX?
Innovator IBD 50 ETF has a quarterly dividend of $0.26 per share corresponding to a yield of 0.78%. First Trust US Equity Opportunities ETF offers a yield of 0.14% to investors and pays a quarterly dividend of $0.09 per share. Innovator IBD 50 ETF pays -- of its earnings as a dividend. First Trust US Equity Opportunities ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FFTY or FPX?
Innovator IBD 50 ETF quarterly revenues are --, which are smaller than First Trust US Equity Opportunities ETF quarterly revenues of --. Innovator IBD 50 ETF's net income of -- is lower than First Trust US Equity Opportunities ETF's net income of --. Notably, Innovator IBD 50 ETF's price-to-earnings ratio is -- while First Trust US Equity Opportunities ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovator IBD 50 ETF is -- versus -- for First Trust US Equity Opportunities ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FFTYInnovator IBD 50 ETF-- -- -- -- FPXFirst Trust US Equity Opportunities ETF-- -- -- --
-
Which has Higher Returns FFTY or IPO?
Renaissance IPO ETF has a net margin of -- compared to Innovator IBD 50 ETF's net margin of --. Innovator IBD 50 ETF's return on equity of -- beat Renaissance IPO ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital FFTYInnovator IBD 50 ETF-- -- -- IPORenaissance IPO ETF-- -- -- -
What do Analysts Say About FFTY or IPO?
Innovator IBD 50 ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Renaissance IPO ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Innovator IBD 50 ETF has higher upside potential than Renaissance IPO ETF, analysts believe Innovator IBD 50 ETF is more attractive than Renaissance IPO ETF.
Company Buy Ratings Hold Ratings Sell Ratings FFTYInnovator IBD 50 ETF0 0 0 IPORenaissance IPO ETF0 0 0 -
Is FFTY or IPO More Risky?
Innovator IBD 50 ETF has a beta of 1.319, which suggesting that the stock is 31.878% more volatile than S&P 500. In comparison Renaissance IPO ETF has a beta of 1.306, suggesting its more volatile than the S&P 500 by 30.621%.
-
Which is a Better Dividend Stock FFTY or IPO?
Innovator IBD 50 ETF has a quarterly dividend of $0.26 per share corresponding to a yield of 0.78%. Renaissance IPO ETF offers a yield of 0.38% to investors and pays a quarterly dividend of $0.05 per share. Innovator IBD 50 ETF pays -- of its earnings as a dividend. Renaissance IPO ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FFTY or IPO?
Innovator IBD 50 ETF quarterly revenues are --, which are smaller than Renaissance IPO ETF quarterly revenues of --. Innovator IBD 50 ETF's net income of -- is lower than Renaissance IPO ETF's net income of --. Notably, Innovator IBD 50 ETF's price-to-earnings ratio is -- while Renaissance IPO ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovator IBD 50 ETF is -- versus -- for Renaissance IPO ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FFTYInnovator IBD 50 ETF-- -- -- -- IPORenaissance IPO ETF-- -- -- --
-
Which has Higher Returns FFTY or MDYG?
SPDR S&P 400 Mid Cap Growth ETF has a net margin of -- compared to Innovator IBD 50 ETF's net margin of --. Innovator IBD 50 ETF's return on equity of -- beat SPDR S&P 400 Mid Cap Growth ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital FFTYInnovator IBD 50 ETF-- -- -- MDYGSPDR S&P 400 Mid Cap Growth ETF-- -- -- -
What do Analysts Say About FFTY or MDYG?
Innovator IBD 50 ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P 400 Mid Cap Growth ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Innovator IBD 50 ETF has higher upside potential than SPDR S&P 400 Mid Cap Growth ETF, analysts believe Innovator IBD 50 ETF is more attractive than SPDR S&P 400 Mid Cap Growth ETF.
Company Buy Ratings Hold Ratings Sell Ratings FFTYInnovator IBD 50 ETF0 0 0 MDYGSPDR S&P 400 Mid Cap Growth ETF0 0 0 -
Is FFTY or MDYG More Risky?
Innovator IBD 50 ETF has a beta of 1.319, which suggesting that the stock is 31.878% more volatile than S&P 500. In comparison SPDR S&P 400 Mid Cap Growth ETF has a beta of 1.061, suggesting its more volatile than the S&P 500 by 6.076%.
-
Which is a Better Dividend Stock FFTY or MDYG?
Innovator IBD 50 ETF has a quarterly dividend of $0.26 per share corresponding to a yield of 0.78%. SPDR S&P 400 Mid Cap Growth ETF offers a yield of 0.84% to investors and pays a quarterly dividend of $0.19 per share. Innovator IBD 50 ETF pays -- of its earnings as a dividend. SPDR S&P 400 Mid Cap Growth ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FFTY or MDYG?
Innovator IBD 50 ETF quarterly revenues are --, which are smaller than SPDR S&P 400 Mid Cap Growth ETF quarterly revenues of --. Innovator IBD 50 ETF's net income of -- is lower than SPDR S&P 400 Mid Cap Growth ETF's net income of --. Notably, Innovator IBD 50 ETF's price-to-earnings ratio is -- while SPDR S&P 400 Mid Cap Growth ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovator IBD 50 ETF is -- versus -- for SPDR S&P 400 Mid Cap Growth ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FFTYInnovator IBD 50 ETF-- -- -- -- MDYGSPDR S&P 400 Mid Cap Growth ETF-- -- -- --
-
Which has Higher Returns FFTY or ONEO?
SPDR Russell 1000 Momentum Focus ETF has a net margin of -- compared to Innovator IBD 50 ETF's net margin of --. Innovator IBD 50 ETF's return on equity of -- beat SPDR Russell 1000 Momentum Focus ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital FFTYInnovator IBD 50 ETF-- -- -- ONEOSPDR Russell 1000 Momentum Focus ETF-- -- -- -
What do Analysts Say About FFTY or ONEO?
Innovator IBD 50 ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR Russell 1000 Momentum Focus ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Innovator IBD 50 ETF has higher upside potential than SPDR Russell 1000 Momentum Focus ETF, analysts believe Innovator IBD 50 ETF is more attractive than SPDR Russell 1000 Momentum Focus ETF.
Company Buy Ratings Hold Ratings Sell Ratings FFTYInnovator IBD 50 ETF0 0 0 ONEOSPDR Russell 1000 Momentum Focus ETF0 0 0 -
Is FFTY or ONEO More Risky?
Innovator IBD 50 ETF has a beta of 1.319, which suggesting that the stock is 31.878% more volatile than S&P 500. In comparison SPDR Russell 1000 Momentum Focus ETF has a beta of 0.987, suggesting its less volatile than the S&P 500 by 1.294%.
-
Which is a Better Dividend Stock FFTY or ONEO?
Innovator IBD 50 ETF has a quarterly dividend of $0.26 per share corresponding to a yield of 0.78%. SPDR Russell 1000 Momentum Focus ETF offers a yield of 1.35% to investors and pays a quarterly dividend of $0.42 per share. Innovator IBD 50 ETF pays -- of its earnings as a dividend. SPDR Russell 1000 Momentum Focus ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FFTY or ONEO?
Innovator IBD 50 ETF quarterly revenues are --, which are smaller than SPDR Russell 1000 Momentum Focus ETF quarterly revenues of --. Innovator IBD 50 ETF's net income of -- is lower than SPDR Russell 1000 Momentum Focus ETF's net income of --. Notably, Innovator IBD 50 ETF's price-to-earnings ratio is -- while SPDR Russell 1000 Momentum Focus ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovator IBD 50 ETF is -- versus -- for SPDR Russell 1000 Momentum Focus ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FFTYInnovator IBD 50 ETF-- -- -- -- ONEOSPDR Russell 1000 Momentum Focus ETF-- -- -- --
-
Which has Higher Returns FFTY or TPLE?
Timothy Plan US Large/Mid Core Enhanced ETF has a net margin of -- compared to Innovator IBD 50 ETF's net margin of --. Innovator IBD 50 ETF's return on equity of -- beat Timothy Plan US Large/Mid Core Enhanced ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital FFTYInnovator IBD 50 ETF-- -- -- TPLETimothy Plan US Large/Mid Core Enhanced ETF-- -- -- -
What do Analysts Say About FFTY or TPLE?
Innovator IBD 50 ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Timothy Plan US Large/Mid Core Enhanced ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Innovator IBD 50 ETF has higher upside potential than Timothy Plan US Large/Mid Core Enhanced ETF, analysts believe Innovator IBD 50 ETF is more attractive than Timothy Plan US Large/Mid Core Enhanced ETF.
Company Buy Ratings Hold Ratings Sell Ratings FFTYInnovator IBD 50 ETF0 0 0 TPLETimothy Plan US Large/Mid Core Enhanced ETF0 0 0 -
Is FFTY or TPLE More Risky?
Innovator IBD 50 ETF has a beta of 1.319, which suggesting that the stock is 31.878% more volatile than S&P 500. In comparison Timothy Plan US Large/Mid Core Enhanced ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock FFTY or TPLE?
Innovator IBD 50 ETF has a quarterly dividend of $0.26 per share corresponding to a yield of 0.78%. Timothy Plan US Large/Mid Core Enhanced ETF offers a yield of 0.94% to investors and pays a quarterly dividend of $0.02 per share. Innovator IBD 50 ETF pays -- of its earnings as a dividend. Timothy Plan US Large/Mid Core Enhanced ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FFTY or TPLE?
Innovator IBD 50 ETF quarterly revenues are --, which are smaller than Timothy Plan US Large/Mid Core Enhanced ETF quarterly revenues of --. Innovator IBD 50 ETF's net income of -- is lower than Timothy Plan US Large/Mid Core Enhanced ETF's net income of --. Notably, Innovator IBD 50 ETF's price-to-earnings ratio is -- while Timothy Plan US Large/Mid Core Enhanced ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovator IBD 50 ETF is -- versus -- for Timothy Plan US Large/Mid Core Enhanced ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FFTYInnovator IBD 50 ETF-- -- -- -- TPLETimothy Plan US Large/Mid Core Enhanced ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
68
MCRI alert for Jul 18
Monarch Casino & Resort [MCRI] is up 19.81% over the past day.
Sell
41
NEGG alert for Jul 18
Newegg Commerce [NEGG] is up 17.85% over the past day.
Buy
72
MNPR alert for Jul 18
Monopar Therapeutics [MNPR] is up 13.2% over the past day.
